| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Amelubant targets the leukotriene B4 (LTB4) receptor, a G protein-coupled receptor that mediates the pro-inflammatory effects of LTB4. LTB4 is a potent chemoattractant for neutrophils and other immune cells, and it plays a critical role in the pathogenesis of various inflammatory diseases, including asthma, rheumatoid arthritis, and inflammatory bowel disease. Amelubant is a prodrug of active metabolites BIIL 260 and BIIL 315. These metabolites are reversible and competitive LTB4 receptor antagonists, with Kis of 1.4, 1.1 nM and 1.7, 1.9 nM in vital cells and membranes, respectively. By blocking the LTB4 receptor, Amelubant and its metabolites inhibit LTB4-mediated chemotaxis and activation of immune cells, thereby reducing inflammation.
|
|---|---|
| ln Vitro |
Amelubant is a prodrug of the active metabolites BIIL 260 and BIIL 315, which have Kis values of 1.4, 1.1 nM and 1.7, 1.9 nM in living cells and cell membranes, respectively. These metabolites are competitive and reversible LTB4 receptor antagonists [1].
In vitro studies have characterized Amelubant as a prodrug of potent LTB4 receptor antagonists. The active metabolites BIIL 260 and BIIL 315 are reversible and competitive LTB4 receptor antagonists. They have Kis of 1.4, 1.1 nM and 1.7, 1.9 nM in vital cells and membranes, respectively. Amelubant itself negligibly binds to the LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. These findings confirm that Amelubant is a prodrug that is converted to active metabolites with potent LTB4 receptor antagonist activity. |
| ln Vivo |
In vivo studies have demonstrated that Amelubant has anti-inflammatory activity. As an orally active and long-acting LTB4 receptor antagonist, Amelubant has been investigated for the treatment of inflammatory diseases. However, specific in vivo protocols and results, such as dosing regimens, routes of administration, and efficacy in disease models, are not detailed in the available literature. Amelubant is used as a research tool to study LTB4 receptor-mediated inflammation and to validate LTB4 as a therapeutic target.
|
| Enzyme Assay |
The in vitro assays for Amelubant measure its binding to the LTB4 receptor and its ability to inhibit LTB4-mediated responses. Receptor binding assays are performed using membranes from cells expressing the LTB4 receptor and a radiolabeled LTB4 ligand. The Kis for Amelubant and its metabolites are determined from competition curves. Functional assays measure the inhibition of LTB4-induced chemotaxis or calcium mobilization in immune cells. These assays confirm that Amelubant is a prodrug that is converted to active metabolites with potent LTB4 receptor antagonist activity.
|
| Cell Assay |
In vitro cell-based assays for Amelubant are used to study its effects on LTB4-mediated immune cell function. Neutrophils or other immune cells are treated with LTB4 in the presence or absence of Amelubant or its metabolites. Chemotaxis is measured using transwell migration assays. The production of reactive oxygen species or the release of inflammatory mediators can also be assessed. The compound's ability to inhibit LTB4-induced responses is measured. These cell-based assays confirm that Amelubant and its metabolites are potent antagonists of LTB4 receptor-mediated immune cell activation.
|
| Animal Protocol |
In vivo animal experiments for Amelubant would typically be conducted in models of inflammatory diseases, such as models of asthma, rheumatoid arthritis, or inflammatory bowel disease. In a typical study, Amelubant is administered orally to animals, and the effects on inflammation are assessed. Endpoints would include the measurement of inflammatory cell infiltration, cytokine levels, and tissue damage. However, specific protocols for Amelubant are not detailed in the available literature. Amelubant is a prodrug that is converted to active metabolites in vivo.
|
| ADME/Pharmacokinetics |
Amelubant has a molecular weight of 538.63 g/mol and a molecular formula of C33H34N2O5. It is a solid compound. For storage, it is recommended to keep the powder at -20°C for up to 3 years. In solvent, it can be stored at -80°C for 1 year. Pharmacokinetic properties have been studied, and Amelubant is an orally active prodrug. Detailed pharmacokinetic parameters, such as absorption, distribution, metabolism, and excretion, are not extensively detailed in the available literature.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for Amelubant is not provided in standard product descriptions. As a research compound, its toxicity profile has not been extensively characterized. Amelubant is a prodrug of LTB4 receptor antagonists, and its toxicity would be related to the effects of LTB4 receptor blockade on immune function. As with all research chemicals, standard laboratory safety precautions should be followed when handling Amelubant. Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References | |
| Additional Infomation |
Drug Indication
It has been studied for the treatment of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and rheumatoid arthritis. Mechanism of Action Ameruban is a long-acting oral leukotriene B4 (LTB4) receptor antagonist. Ameruban is a prodrug that is metabolized by ubiquitous esterases to BIIL 260 and its glucuronidated metabolite BIIL 315.14. BIIL 260 and BIIL 315.14 interact directly with the LTB4 receptor. LTB4 is a chemokine of immune cells that enhances immune responses. G protein-coupled receptors BLT1 (with high affinity for LTB4 and expressed in most leukocytes) and BLT2 (with low affinity for LTB4) are responsible for mediating the action of LTB4. Amelubant (BIIL 284) is a research compound and is not approved for any clinical or therapeutic use. It is a potent, orally active, and long-acting leukotriene B4 (LTB4) receptor antagonist. Amelubant is a prodrug of active metabolites BIIL 260 and BIIL 315. The active metabolites are reversible and competitive LTB4 receptor antagonists, with Kis of 1.4, 1.1 nM and 1.7, 1.9 nM in vital cells and membranes, respectively. Amelubant has anti-inflammatory activity. It is used to study LTB4 receptor-mediated inflammation and to explore potential treatments for inflammatory diseases. Its mechanism of action involves being converted to active metabolites that block the LTB4 receptor, thereby inhibiting LTB4-mediated immune cell activation and inflammation. |
| Molecular Formula |
C33H34N2O5
|
|---|---|
| Molecular Weight |
538.644
|
| Exact Mass |
568.294
|
| CAS # |
346735-24-8
|
| PubChem CID |
135564996
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.512
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
40
|
| Complexity |
780
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SBVYURPQULDJTI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H34N2O5/c1-4-38-32(37)35-31(34)25-8-16-29(17-9-25)39-21-23-6-5-7-24(20-23)22-40-30-18-12-27(13-19-30)33(2,3)26-10-14-28(36)15-11-26/h5-20,36H,4,21-22H2,1-3H3,(H2,34,35,37)
|
| Chemical Name |
ethyl N-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidoyl]carbamate
|
| Synonyms |
Amelubant BIIL-284-BS BIIL-284
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~185.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8565 mL | 9.2826 mL | 18.5653 mL | |
| 5 mM | 0.3713 mL | 1.8565 mL | 3.7131 mL | |
| 10 mM | 0.1857 mL | 0.9283 mL | 1.8565 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02265653 | COMPLETED | Drug: BIIL 284 BS tablet C Drug: BIIL 284 BS tablet D Drug: BIIL 284 BS WIF tablet |
Healthy | Boehringer Ingelheim | 1999-11 | Phase 1 |
| NCT02265627 | COMPLETED | Drug: BIIL 284 BS | Hepatic Insufficiency | Boehringer Ingelheim | 2000-03 | Phase 1 |
| NCT02266550 | COMPLETED | Drug: [14C] BILL 284 BS | Healthy | Boehringer Ingelheim | 1999-10 | Phase 1 |
| NCT02265640 | COMPLETED | Drug: BIIL 284 BS boli Drug: BIIL 284 BS tablet C Other: standard breakfast |
Healthy | Boehringer Ingelheim | 2000-10 | Phase 1 |
| NCT02268149 | COMPLETED | Drug: BIIL 284 BS Drug: Prednisone Drug: Placebo |
Healthy | Boehringer Ingelheim | 2000-04 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
